About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5527337
Allelic
Composition
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EML4/ALK)Kkw mutation (0 available); any Col1a1 mutation (88 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice exhibit a median survival of 7 to 8 weeks

neoplasm
• withdrawal of doxycycline leads to complete tumor regression
• ALK kinase inhibitor is a more effective therapy than chemotherapy in doxycycline-treated mice
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

growth/size/body
• in tumor-bearing, doxycycline-treated mice in the first 4 weeks

respiratory system
N
• untreated mice exhibit normal lung histology
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:166724


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
05/24/2016
MGI 6.04
The Jackson Laboratory